• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.产生复杂重组蛋白的组织工程细胞在体内抑制卵巢癌。
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9. doi: 10.1073/pnas.051625998. Epub 2001 Feb 27.
2
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.高度纯化的苗勒管抑制物质在体内可抑制人类卵巢癌。
Clin Cancer Res. 2002 Aug;8(8):2640-6.
3
Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.苗勒管抑制物质的裂解在体内激活抗增殖作用。
Clin Cancer Res. 1995 Mar;1(3):343-9.
4
Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.长期表达苗勒氏管抑制物质的转基因小鼠的性发育异常。
Nature. 1990 May 10;345(6271):167-70. doi: 10.1038/345167a0.
5
Thyroid hormone and follicle-stimulating hormone regulate Müllerian-inhibiting substance messenger ribonucleic acid expression in cultured neonatal rat Sertoli cells.甲状腺激素和促卵泡激素调节培养的新生大鼠支持细胞中苗勒管抑制物质信使核糖核酸的表达。
Endocrinology. 1998 Nov;139(11):4489-95. doi: 10.1210/endo.139.11.6315.
6
Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.重组苗勒管抑制物质对妇科肿瘤细胞系和肿瘤外植体的抗增殖作用极小。
Cancer Res. 1989 Apr 15;49(8):2005-11.
7
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.重组人苗勒管抑制物质在体内抑制II型苗勒管抑制物质受体定向转基因小鼠卵巢癌的长期生长。
Clin Cancer Res. 2006 Mar 1;12(5):1593-8. doi: 10.1158/1078-0432.CCR-05-2108.
8
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.人卵巢癌、细胞系和原发性腹水细胞表达人苗勒管抑制物质(MIS)II型受体,能结合MIS并对其产生反应。
Clin Cancer Res. 1999 Nov;5(11):3488-99.
9
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.苗勒管抑制物质在体外和体内调节前列腺中的核因子-κB信号通路。
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44. doi: 10.1073/pnas.221599298. Epub 2002 Jan 2.
10
Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.重组人苗勒管抑制物质在体外和体内均能抑制人眼黑色素瘤细胞系。
Cancer Res. 1992 Mar 1;52(5):1182-6.

引用本文的文献

1
Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer.靶向放射性药物:卵巢癌研究不足的策略。
Theranostics. 2024 Sep 30;14(16):6281-6300. doi: 10.7150/thno.99782. eCollection 2024.
2
Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.九组队列研究中的抗苗勒管激素与卵巢癌风险
Int J Cancer. 2018 Jan 15;142(2):262-270. doi: 10.1002/ijc.31058. Epub 2017 Oct 4.
3
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.糖基工程化人源化抗MISRII抗体3C23K在卵巢癌模型中的抗肿瘤疗效主要由免疫效应细胞的参与介导。
Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715.
4
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.在患者来源的卵巢癌异种移植模型中,腺相关病毒9型携带修饰的人苗勒管抑制物质作为基因疗法。
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4418-27. doi: 10.1073/pnas.1510604112. Epub 2015 Jul 27.
5
Evaluation of tissue interactions with mechanical elements of a transscleral drug delivery device.评估巩膜给药装置机械元件与组织的相互作用。
Pharmaceutics. 2012 Mar 12;4(1):212-29. doi: 10.3390/pharmaceutics4010212.
6
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.苗勒管抑制物质增强亚临床剂量的化疗药物对人及小鼠卵巢癌的抑制作用。
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. doi: 10.1073/pnas.0607959103. Epub 2006 Nov 6.
7
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.苗勒管抑制物质在C3(1)T抗原转基因小鼠乳腺癌模型中抑制肿瘤生长。
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3219-24. doi: 10.1073/pnas.0409709102. Epub 2005 Feb 22.
8
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.子宫内膜癌是苗勒管抑制物质的受体介导靶点。
Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6. doi: 10.1073/pnas.0407772101. Epub 2004 Dec 23.
9
The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.抗苗勒管激素II型受体:关于单克隆抗体和天然配体识别的结合域的见解
Biochem J. 2004 May 1;379(Pt 3):785-93. doi: 10.1042/BJ20031961.
10
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.苗勒管抑制物质通过一条涉及p130和p107的信号通路抑制宫颈癌细胞生长。
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6. doi: 10.1073/pnas.2636900100. Epub 2003 Dec 11.

本文引用的文献

1
Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.苗勒管抑制物质通过一种不依赖Rb的机制抑制卵巢细胞生长。
J Biol Chem. 2000 Nov 24;275(47):37101-9. doi: 10.1074/jbc.M005701200.
2
Controlling TGF-beta signaling.控制转化生长因子-β信号传导。
Genes Dev. 2000 Mar 15;14(6):627-44.
3
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.人卵巢癌、细胞系和原发性腹水细胞表达人苗勒管抑制物质(MIS)II型受体,能结合MIS并对其产生反应。
Clin Cancer Res. 1999 Nov;5(11):3488-99.
4
Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation.组织工程学:用于外科重建和移植的活体替代装置的设计与制造。
Lancet. 1999 Jul;354 Suppl 1:SI32-4. doi: 10.1016/s0140-6736(99)90247-7.
5
Cancer statistics, 1999.1999年癌症统计数据。
CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1. doi: 10.3322/canjclin.49.1.8.
6
Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.苗勒管抑制物质的裂解在体内激活抗增殖作用。
Clin Cancer Res. 1995 Mar;1(3):343-9.
7
Biological therapy of ovarian cancer: current directions.卵巢癌的生物治疗:当前方向
Semin Oncol. 1998 Jun;25(3):381-96.
8
Pathology of ovarian cancer precursors.卵巢癌前病变的病理学
J Cell Biochem Suppl. 1995;23:208-18. doi: 10.1002/jcb.240590928.
9
Developmental expression of a candidate müllerian inhibiting substance type II receptor.
Endocrinology. 1996 Jan;137(1):160-5. doi: 10.1210/endo.137.1.8536608.
10
Transplantation of genetically altered hepatocytes using cell-polymer constructs.使用细胞-聚合物构建体进行基因改造肝细胞的移植。
Transplant Proc. 1993 Feb;25(1 Pt 2):1002-4.

产生复杂重组蛋白的组织工程细胞在体内抑制卵巢癌。

Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

作者信息

Stephen A E, Masiakos P T, Segev D L, Vacanti J P, Donahoe P K, MacLaughlin D T

机构信息

Pediatric Surgical Research Laboratories, Department of Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.

出版信息

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9. doi: 10.1073/pnas.051625998. Epub 2001 Feb 27.

DOI:10.1073/pnas.051625998
PMID:11248058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC30633/
Abstract

Techniques of tissue engineering and cell and molecular biology were used to create a biodegradable scaffold for transfected cells to produce complex proteins. Mullerian Inhibiting Substance (MIS) causes regression of Mullerian ducts in the mammalian embryo. MIS also causes regression in vitro of ovarian tumor cell lines and primary cells from ovarian carcinomas, which derive from Mullerian structures. In a strategy to circumvent the complicated purification protocols for MIS, Chinese hamster ovary cells transfected with the human MIS gene were seeded onto biodegradable polymers of polyglycolic acid fibers and secretion of MIS confirmed. The polymer-cell graft was implanted into the right ovarian pedicle of severe combined immunodeficient mice. Serum MIS in the mice rose to supraphysiologic levels over time. One week after implantation of the polymer-cell graft, IGROV-1 human tumors were implanted under the renal capsule of the left kidney. Growth of the IGROV-1 tumors was significantly inhibited in the animals with a polymer-cell graft of MIS-producing cells, compared with controls. This novel MIS delivery system could have broader applications for other inhibitory agents not amenable to efficient purification and provides in vivo evidence for a role of MIS in the treatment of ovarian cancer.

摘要

利用组织工程技术以及细胞与分子生物学方法,构建了一种可生物降解的支架,用于转染细胞以产生复杂蛋白质。苗勒管抑制物质(MIS)可导致哺乳动物胚胎中的苗勒管退化。MIS还能在体外使源自苗勒管结构的卵巢肿瘤细胞系和原发性卵巢癌细胞发生退化。为规避MIS复杂的纯化方案,将转染了人MIS基因的中国仓鼠卵巢细胞接种到聚乙醇酸纤维的可生物降解聚合物上,并证实了MIS的分泌。将聚合物 - 细胞移植物植入重度联合免疫缺陷小鼠的右侧卵巢蒂。随着时间的推移,小鼠血清中的MIS升高至超生理水平。在植入聚合物 - 细胞移植物一周后,将IGROV - 1人肿瘤植入左肾的肾包膜下。与对照组相比,在植入了产生MIS细胞的聚合物 - 细胞移植物的动物中,IGROV - 1肿瘤的生长受到显著抑制。这种新型的MIS递送系统可能对其他难以高效纯化的抑制剂有更广泛的应用,并为MIS在卵巢癌治疗中的作用提供了体内证据。